Curated News
By: NewsRamp Editorial Staff
May 13, 2025
Oragenics Granted Approval to Commence Phase II Trial for Neuroprotective Therapy
TLDR
- Oragenics (NYSE American: OGEN) gains HREC approval for Phase II trial of ONP-002, enhancing market position.
- ONP-002 Phase II trial for mTBI treatment approved by Australia's HREC, starting patient enrollment in Q2 2025.
- Oragenics' ONP-002 therapy offers hope for better treatment of concussion, advancing neuroprotective solutions globally.
- Innovative intranasal neuroprotective therapy ONP-002 shows promise in reducing brain inflammation and swelling, potentially revolutionizing mTBI treatment.
Impact - Why it Matters
This news matters because it signifies a significant step in the development of a potential treatment for mild traumatic brain injury. The approval for the clinical trial opens doors for Oragenics to expand its program internationally, potentially benefiting patients suffering from concussions globally.
Summary
Oragenics, a biotechnology company, received approval to start a Phase II clinical trial of its neuroprotective therapy for mild traumatic brain injury. The trial will enroll patients at Level 1 trauma emergency departments in Australia, with potential expansion to New Zealand. The therapy, ONP-002, aims to reduce inflammation, oxidative stress, and brain swelling.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Oragenics Granted Approval to Commence Phase II Trial for Neuroprotective Therapy
